The Impact of Acute Exercise on Hemostasis and Angiogenesis Mediators in Patients With Continuous-Flow Left Ventricular Assist Devices: A Prospective Observational Pilot Study.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
Impaired primary hemostasis and dysregulated angiogenesis, known as a two-hit hypothesis, are associated with gastrointestinal (GI) bleeding in patients with continuous-flow left ventricular assist devices (CF-LVADs). Exercise is known to influence hemostasis and angiogenesis in healthy individuals; however, little is known about the effect in patients with CF-LVADs. The objective of this prospective observational study was to determine whether acute exercise modulates two-hit hypothesis mediators associated with GI bleeding in patients with a CF-LVAD. Twenty-two patients with CF-LVADs performed acute exercise either on a cycle ergometer for approximately 10 minutes or on a treadmill for 30 minutes. Blood samples were taken pre- and post-exercise to analyze hemostatic and angiogenic biomarkers. Acute exercise resulted in an increased platelet count (p < 0.00001) and platelet function (induced by adenosine diphosphate, p = 0.0087; TRAP-6, p = 0.0005; ristocetin, p = 0.0009). Additionally, high-molecular-weight vWF multimers (p < 0.00001), vWF collagen-binding activity (p = 0.0012), factor VIII (p = 0.034), angiopoietin-1 (p = 0.0026), and vascular endothelial growth factor (p = 0.0041) all increased after acute exercise. This pilot work demonstrates that acute exercise modulated two-hit hypothesis mediators associated with GI bleeding in patients with CF-LVADs.
Identifiants
pubmed: 38833540
doi: 10.1097/MAT.0000000000002246
pii: 00002480-990000000-00501
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Belgian Fonds voor Hartchirurgie
ID : N. 489618
Organisme : the National Health and Medical Research Council Centre
ID : APP1079421
Informations de copyright
Copyright © ASAIO 2024.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
Rogers JG, Pagani FD, Tatooles AJ, et al.: Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 376: 451–460, 2017.
Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators: A fully magnetically levitated left ventricular assist device—Final report. N Engl J Med 380: 1618–1627, 2019.
Patel SR, Vukelic S, Jorde UP: Bleeding in continuous flow left ventricular assist device recipients: An acquired vasculopathy? J Thorac Dis 8: E1321–E1327, 2016.
Bartoli CR, Zhang DM, Hennessy-Strahs S, et al.: Clinical and in vitro evidence that left ventricular assist device-induced von Willebrand factor degradation alters angiogenesis. Circ Heart Fail 11: e004638, 2018.
Roka-Moiia Y, Miller-Gutierrez S, Palomares DE, et al.: Platelet dysfunction during mechanical circulatory support: Elevated shear stress promotes downregulation of α(IIb)β(3) and GPIb via microparticle shedding decreasing platelet aggregability. Arterioscler Thromb Vasc Biol 41: 1319–1336, 2021.
Geisen U, Brehm K, Trummer G, et al.: Platelet secretion defects and acquired von Willebrand syndrome in patients with ventricular assist devices. J Am Heart Assoc 7: e006519, 2018.
Vincent F, Rauch A, Loobuyck V, et al.: Arterial pulsatility and circulating von Willebrand factor in patients on mechanical circulatory support. J Am Coll Cardiol 71: 2106–2118, 2018.
Patel SR, Vukelic S, Chinnadurai T, et al.: Gastrointestinal angiodysplasia in heart failure and during CF LVAD support. J Heart Lung Transplant 41: 129–132, 2022.
Kang J, Hennessy-Strahs S, Kwiatkowski P, et al.: Continuous-flow LVAD support causes a distinct form of intestinal angiodysplasia. Circ Res 121: 963–969, 2017.
Starke RD, Ferraro F, Paschalaki KE, et al.: Endothelial von Willebrand factor regulates angiogenesis. Blood 117: 1071–1080, 2011.
Selvam S, James P, James P: Angiodysplasia in von Willebrand disease: Understanding the clinical and basic science. Semin Thromb Hemost 43: 572–580, 2017.
Randi AM, Laffan MA, Starke RD: Von Willebrand factor, angiodysplasia and angiogenesis. Mediterr J Hematol Infect Dis 5: e2013060, 2013.
Tabit CE, Chen P, Kim GH, et al.: Elevated angiopoietin-2 level in patients with continuous-flow left ventricular assist devices leads to altered angiogenesis and is associated with higher nonsurgical bleeding. Circulation 134: 141–152, 2016.
Tabit CE, Coplan MJ, Chen P, Jeevanandam V, Uriel N, Liao JK: Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices. J Heart Lung Transplant 37: 107–115, 2018.
Kicken CH, Miszta A, Kelchtermans H, De Laat B: Hemostasis during extreme exertion. Semin Thromb Hemost 44: 640–650, 2018.
Hoier B, Nordsborg N, Andersen S, et al.: Pro- and anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol 590: 595–606, 2012.
Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377–381, 1982.
Fresiello L, Jacobs S, Timmermans P, et al.: Limiting factors of peak and submaximal exercise capacity in LVAD patients. PLoS One 15: e0235684, 2020.
Chan CHH, Inoue M, Ki KK, et al.: Shear-dependent platelet aggregation size. Artif Organs 44: 1286–1295, 2020.
Bobenko A, Schoenrath F, Knierim JH, et al.: Exercise training in patients with a left ventricular assist device (Ex-VAD): Rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. Eur J Heart Fail 21: 1152–1159, 2019.
Adamopoulos S, Corrà U, Laoutaris ID, et al.: Exercise training in patients with ventricular assist devices: A review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21: 3–13, 2019.
Moreno-Suarez I, Scheer A, Lam K, et al.: High-intensity interval training in patients with left ventricular assist devices: A pilot randomized controlled trial. J Heart Lung Transplant 39: 1380–1388, 2020.
Uriel N, Pak SW, Jorde UP, et al.: Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 56: 1207–1213, 2010.
John R, Panch S, Hrabe J, et al.: Activation of endothelial and coagulation systems in left ventricular assist device recipients. Ann Thorac Surg 88: 1171–1179, 2009.
Klaeske K, Dieterlen MT, Eifert S, et al.: Device-induced platelet dysfunction in patients after left ventricular assist device implantation. J Thromb Haemost 19: 1331–1341, 2021.
Klaeske K, Dieterlen MT, Scholz U, et al.: Acquired von Willebrand factor deficiency is reduced in HeartMate 3 patients. Eur J Cardiothorac Surg 56: 444–450, 2019.
Wever-Pinzon O, Selzman CH, Drakos SG, et al.: Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 6: 517–526, 2013.
Birschmann I, Dittrich M, Eller T, et al.: Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 33: 80–87, 2014.
Lenting PJ, Casari C, Christophe OD, Denis CV: von Willebrand factor: The old, the new and the unknown. J Thromb Haemost 10: 2428–2437, 2012.
Randi AM, Smith KE, Castaman G: von Willebrand factor regulation of blood vessel formation. Blood 132: 132–140, 2018.
Martínez CE, Smith PC, Palma Alvarado VA: The influence of platelet-derived products on angiogenesis and tissue repair: A concise update. Front Physiol 6: 290, 2015.
Brouwers J, Noviyanti R, Fijnheer R, et al.: Platelet activation determines angiopoietin-1 and VEGF levels in malaria: Implications for their use as biomarkers. PLoS One 8: e64850, 2014.
Kisucka J, Butterfield CE, Duda DG, et al.: Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 103: 855–860, 2006.
Cushing M, Kawaguchi K, Friedman KD, Mark T: Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion 52: 1535–1541, 2012.
Deconinck SJ, Nix C, Barth S, et al.: ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation. J Thromb Haemost 20: 2797–2809, 2022.
Bartoli CR, Kang J, Restle DJ, et al.: Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiological shear stress: Therapeutic implications for left ventricular assist device-associated bleeding. JACC Heart Fail 3: 860–869, 2015.
Imamura T, Kinugawa K, Uriel N: Therapeutic strategy for gastrointestinal bleeding in patients with left ventricular assist device. Circ J 82: 2931–2938, 2018.
Katz JN, Adamson RM, John R, et al.; TRACE study: Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. J Heart Lung Transplant 34: 1542–1548, 2015.
Andreas M, Moayedifar R, Wieselthaler G, et al.: Increased thromboembolic events with dabigatran compared with vitamin k antagonism in left ventricular assist device patients: A randomized controlled pilot trial. Circ Heart Fail 10: e003709, 2017.
Dill DB, Costill DL: Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 37: 247–248, 1974.